Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2408-2416

  Tyler, Matthew A ^a   Ulasov, Ilya V ^a   Borovjagin, Anton ^b   Sonabend, Adam M ^a   Khramtsov, Andrey ^a   Han, Yu ^a   Dent, Paul ^c   Fisher, Paul B ^d   Curiel, David T ^b   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Alabama at Birmingham   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; INTEGRIN; VITRONECTIN RECEPTOR;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ADENOVIRIDAE; ANIMALS; BRAIN NEOPLASMS; FLOW CYTOMETRY; GENE THERAPY; GLIOMA; HUMANS; INTEGRINS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749556424     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0187     Document Type: Article

References (48)

1. Lesniak MS, Brem H. Targeted therapy for brain tumours. Nat Rev Drug Discov 2004;3:499-508.
2. Stupp R, Weber DC. The role of radio- and chemotherapy in glioblastoma. Onkologie 2005;28:315-7.
3. Gaspar LE, Fisher BJ, Macdonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 1991;24:55-7.
4. Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004; 10:958-66.
5. Puumalainen AM, Vapalahti M, Agrawal RS, et al. β-Galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum Gene Ther 1998;9: 1769-74.
6. Trask TW, Trask RP, Aguilar-Cordova E, et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000;1:195-203.
7. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 2000;11:2197-205.
8. Eck SL, Alavi JB, Judy K, et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-β (H5.010CMVhIFN-β): a phase I trial. Hum Gene Ther 2001; 12:97-113.
9. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 2003;7: 851-8.
10. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003;21:2508-18.
11. Huang KC, Altinoz M, Wosik K, et al. Impact of the coxsackie and adenovirus receptor (CAR) on glioma cell growth and invasion: requirement for the C-terminal domain. Int J Cancer 2005;113: 738-45.
12. Kim M, Sumerel LA, Belousova N, et al. The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells. Br J Cancer 2003;88:1411-6.
13. Asaoka K, Tada M, Sawamura Y, Ikeda J, Abe H. Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the Coxsackievirus and adenovirus receptor. J Neurosurg 2000;92:1002-8.
14. Fuxe J, Liu L, Malin S, Philipson L, Collins VP, Pettersson RF. Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int J Cancer 2003; 103:723-9.
15. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002;62: 5736-42.
16. Haviv YS, Blackwell JL, Kanerva A, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res 2002;62:4273-81.
17. Wu H, Seki T, Dmitriev I, et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647-53.
18. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997;71:4782-90.
19. Stevenson SC, Rollence M, White B, Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995;69:2850-7.
20. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70:2116-23.
21. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996;70:6839-46.
22. Roelvink PW, Kovesdi I, Wickham TJ. Comparative analysis of adenovirus fiber-cell interaction: adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J Virol 1996;70:7614-21.
23. Ulasov IV, Tyler MA, Zeng S, Han Y, Lesniak MS. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther 2006;17:556-64.
24. Bouri K, Feero WG, Myerburg MM, et al. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Hum Gene Ther 1999;10:1633-40.
25. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997;71:8221-9.
26. Mattern RH, Read SB, Pierschbacher MD, Sze CI, Eliceiri BP, Kruse CA. Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. Cancer Ther 2005;3A:325-40.
27. Bello L, Francolini M, Marthyn P, et al. M. α(v)β3 and α(v)β5 integrin expression in glioma periphery. Neurosurgery 2001;49:380-9; discussion 390.
28. MacDonald TJ, Ladisch S. Antisense to integrin α v inhibits growth and induces apoptosis in medulloblastoma cells. Anticancer Res 2001;21: 3785-91.
29. Lim M, Guccione S, Haddix T, et al. α(v)β(3) Integrin in central nervous system tumors. Hum Pathol 2005;36:665-9.
30. Puduvalli VK. Inhibition of angiogenesis as a therapeutic strategy against brain tumors. Cancer Treat Res 2004;117:307-36.
31. Abdollah A, Griggs DW, Zieher H, et al. Inhibition of α(v)β3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11:6270-9.
32. Koizumi N, Mizuguchi H, Hosono T, et al. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim Biophys Acts 2001;1568:13-20.
33. Krasnyk V, Belousova N, Korokhov N, Mikheeva G, Curial DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001;75:4176-83.
34. Takayama K, Reynolds PN, Short JJ, et al. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 2003;309:282-93.
35. Borovjagin AV, Krendelchtchikov A, Ramesh N, Yu DC, Douglas JT, Curiel DT. Complex mosaicism is a novel approach to infectivity enhancement of adenovirus type 5-based vectors. Cancer Gene Ther 2005;12:475-86.
36. Maizel JV, Jr., White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968;36:115-25.
37. Maizel JV, Jr., White DO, Scharff MD. The polypeptides of adenovirus. II. Soluble proteins, cores, top components and the structure of the virion. Virology 1968;36:126-36.
38. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996;70: 7498-509.
39. Lucas A, Kremer EJ, Hemmi S, Luis J, Vignon F, Lazennec G. Comparative transductions of breast cancer cells by three DNA viruses. Biochem Biophys Res Commun 2003;309:1011-6.
40. Tekant Y, Davydova J, Ramirez PJ, Curial DT, Vickers SM, Yamamoto M. Oncolytic adenoviral therapy in gallbladder carcinoma. Surgery 2005; 137:527-35.
41. Zhu ZB, Lu B, Wang M, et al. Transport across a polarized monolayer of Caco-2 cells by transferrin receptor-mediated adenovirus transcytosis. Virology 2004;325:116-28.
42. Taki MKS, Nishizaki M, Mizuguchi H, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ("Telomelysin-RGD"). Oncogene 2005;24:3130-40.
43. Dmitriev IK, Miller CR, Wang M, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
44. Hong JS, Engler JA. Domains required for assembly of adenovirus type 2 fiber trimers. J Virol 1996;70:7071-8.
45. Xia D, Henry U, Gerard RD, Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994;2:1259-70.
46. Belousova N, Krendelchtchikova V, Curial DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002;76:8621-31.
47. McDonald GA, Zhu G, Li Y, Kovesdi I, Wickham TJ, Sukhatme VP. Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector. J Gene Med 1999;1:103-10.
48. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996;14:1570-3.